Nahid A. Qushmaq: Advancing Anticoagulation Through Factor XI/XIa Inhibition
Nahid A. Qushmaq, General Supervisor Assistant for Medical Support Services, Consultant Adult Hematology of Thrombosis and Hemostasis, Head Of Research and Development Department at King Abdullah Medical Complex – Jeddah, shared a post on LinkedIn:
“One of the most valuable sessions I attended at ISTH 2026 was ‘Emerging Therapies in Thrombosis: Factor XI/XIa Inhibitors’, delivered by Dr. Jeffrey Weitz.
The session provided an excellent overview of the evolving role of FXI/FXIa inhibition in thrombosis prevention and highlighted the exciting potential of these novel agents to reduce thrombotic events while minimizing bleeding risk, making it one of the most promising next-generation anticoagulant strategies.
An insightful and thought-provoking session that reinforces how rapidly the field of thrombosis is advancing.”

Stay updates with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders